Questions About Cancer? 1-800-4-CANCER

Gestational Trophoblastic Disease Treatment (PDQ®)

Health Professional Version
Last Modified: 04/12/2013

Changes to This Summary (04/12/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was renamed from Gestational Trophoblastic Tumors and Neoplasia Treatment.

General Information About Gestational Trophoblastic Disease

This section was renamed from General Information About Gestational Trophoblastic Tumors and Neoplasia.

Revised text to state that gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus.

Revised text to state that GTD may be classified as: hydatidiform mole (HM) including complete HM and partial HM; gestational trophoblastic neoplasia including Invasive mole, choriocarcinoma, and placental-site trophoblastic tumor; and, epithelioid trophoblastic tumor.

Cellular Classification of Gestational Trophoblastic Disease

This section was renamed from Cellular Classification of Gestational Trophoblastic Tumors and Neoplasia.

Revised text to state that gestational trophoblastic neoplasia is within the gestational trophoblastic disease classification.

Added text to state that choriocarcinoma, placental-site trophoblastic tumor and epithelioid trophoblastic tumor are often grouped under the heading gestational trophoblastic tumors.

Revised text to state that complete HMs have a 15% to 25% risk of developing into an invasive mole, but transformation to malignancy is much more rare in the case of partial moles.

Added text to state that invasive moles may be preceded by either complete or partial molar pregnancy.

Stage Information for Gestational Trophoblastic Disease

This section was renamed from Stage Information for Gestational Trophoblastic Tumors and Neoplasia.

Hydatidiform Mole (HM) Management

Revised text to state that chemotherapy is determined by the patient's modified World Health Organization score.

Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia Treatment

This section was renamed from Recurrent or Chemoresistant Gestational Trophoblastic Tumor Treatment.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.